TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00789542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic compression
Description: Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine care
Description: Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
Study: NCT03524131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: risk-framed leaflet
Description: 2-sided leaflet, emphasizing health risks of not going to the NHS Health Check

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: benefits-framed leaflet
Description: 2-sided leaflet, emphasizing benefits of attending an NHS Health Check

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: current national leaflet
Description: 4-sided leaflet
Study: NCT00352599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovastatin
Description: Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Study: NCT01553487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forearm vibration
Description: All cases will be trained by forearm vibration device 5 times a week for six weeks period.
Study: NCT02676011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM atropine
Description: Atropine (0.01 mg/kg) (1 ml) IM 30 minutes before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV atropine
Description: Atropine (0.01 mg/kg) intravenously (10 ml) 3 minutes before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine mixed with second dose succinylcholine
Description: Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM normal saline
Description: 1 ml normal saline IM 30 minutes before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM normal saline
Description: 1 ml normal saline IM 30 minutes before induction of anesthesia
Study: NCT01761578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ART18Z Bioresorbable stent
Description: The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.
Study: NCT02676011

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IM normal saline
Description: 1 ml normal saline IM 30 minutes before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV normal saline
Description: IV 10 ml normal saline 3 minutes before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV normal saline
Description: IV 10 ml normal saline 3 minutes before induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline
Description: IV 10 ml normal saline 3 minutes before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline mixed with second dose succinylcholine
Description: Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline mixed with second dose succinylcholine
Description: Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline mixed with second dose succinylcholine
Description: Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
Study: NCT03058757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravesical mitomycin-C 40mg/20ml instillation
Description: neoadjuvant Intravesical mitomycin-C 40mg/20ml instillation~* one day before surgery~* four hours before surgery
Study: NCT01827839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine (GSK1437173A)
Description: 2 doses administered intramuscularly in deltoid region of non-dominant arm.
Study: NCT05364385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
Description: Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
Study: NCT02411409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealtheRx
Description: The HealtheRx is a prescription for community self-care resources. It includes a printed list of self-care resources provided to the patient at an ambulatory visit and tailored based on data from the electronic medical record.
Study: NCT03243721

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 7T MRI
Description: A high field MRI that will take approximately one hour.
Study: NCT05364385

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
Description: Infants in the control group (S/P group) will receive surfactant 2.5 mls/kg and placebo (Normal saline 1mL)
Study: NCT04447287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ASP8062
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: Sublingual

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: buprenorphine/naloxone
Description: Sublingual
Study: NCT04197622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.
Study: NCT03350698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil-9
Description: 3 vaccine series
Study: NCT01732120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Off-clamp partial nephrectomy
Study: NCT02933294

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Triportal pulmonary resection surgery
Description: Uniportal video-assisted thoracoscopic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uniportal pulmonary resection surgery
Description: Triportal video-assisted thoracoscopic surgery
Study: NCT04611334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback
Description: Heart rate variability biological feedback training is carried out in the outpatient meeting room of the hospital, including once a week, 30 minutes of hospital training each time, using Medea physiological feedback device portable Bluetooth physiological signal Feedback system (Medical Device Input No. 027390). Designed as two stages, stage one (the first week) first teaches the subject how to perform abdominal breathing, and connects the physiological feedback device to monitor the patient's breathing and heart rate changes, and sets the breath per minute according to the subject's resonance frequency . Stage two (second-four weeks) guide the case to understand the resonance relationship between breathing and heart rate, and then achieve the effect of matching heart and breath. It is also equipped with a pressure relief device (Helico Inc., New York, NY, USA) for self-practice at home.
Study: NCT00023920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT02485002

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS with ureteral access sheath
Description: Ureteral access sheath will be used during RIRS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIRS without ureteral access sheath
Description: Ureteral access sheath will not be used during RIRS.
Study: NCT03675334

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage with collagen matrix graft
Description: at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Root coverage with subepithelial connective tissue graft
Description: at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Basic periodontal treatment
Description: profilaxis, coronary polishing and scaling and root planning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic periodontal treatment
Description: profilaxis, coronary polishing and scaling and root planning
Study: NCT01397708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INXN-2001
Description: * approximately 1.0 x 1012 viral particles (vp) per injection~* one intratumoral injection of INXN-2001 per study cycle~* maximum of 6 study cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INXN-1001
Description: * 4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)~* 7 oral daily doses of INXN-1001 per study cycle~* maximum of 6 study cycles~* 1 Expansion cohort at a single dose level at or below MTD (160mg/day)
Study: NCT02197026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard drug treatment at the discretion of the investigator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrotherapy
Study: NCT00698789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB019602
Description: 7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administration in AM or PM depending on treatment arm dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administration in AM or PM depending on treatment arm dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administration in AM or PM depending on treatment arm dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administration in AM or PM depending on treatment arm dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administration in AM or PM depending on treatment arm dosing regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration in AM or PM depending on treatment arm dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose metformin monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose metformin monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose metformin monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose metformin monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose metformin monotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Stable dose metformin monotherapy
Study: NCT03243721

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 7T MRI
Description: A high field MRI that will take approximately one hour.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A series of tests to assess memory, verbal skills, and visuospatial skills.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A series of tests to assess memory, verbal skills, and visuospatial skills.
Study: NCT05795907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Capsule / Oral
Study: NCT01343290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Single tablet taken with or without a meal during 2 treatment periods
Study: NCT04653818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velpatasvir/Sofosbuvir
Description: sofosbuvir / velpatasvir will be given for 12 weeks aiming to eradicate HCV. Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant.
Study: NCT02803801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Build Your Parenting Toolkit Program
Description: Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
Study: NCT04944446

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Myofascial release of various muscle groups Treatment of mobilization of the shoulder joint

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Myofascial release of various muscle groups Treatment of mobilization of the shoulder joint
Study: NCT03547791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethason Sodium Phosphate
Description: The antecorticosteroid that will be administered to Group 1 is betamethasone, produced by Dawon Parm(Korea). It contains betamethason sodium phosphate 5.2mg(Betamethasone 4.0mg) in 1 ample(1mL). Each drug is carried in a syringe by pharmacist who does not participate in study after the patient was enrolled in the study and administered to the patient twice 24hours apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intramuscular injection of normal saline 3ml twice 24hours apart
Study: NCT00394407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sliding scale regular insulin
Description: SSRI acqhs
Study: NCT05795907

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Capsule / Oral
Study: NCT00394407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glargine basal insulin and glulisine prandial insulin
Description: glargine insulin once a day and glulisine insulin three times a day as long as patient eating
Study: NCT04737681

Intervention type: OTHER
Intervention: body composition
Description: This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.

Intervention type: OTHER
Intervention: body composition
Description: This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.
Study: NCT02059044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ISTOP-ADE
Description: Interactive Voice Response System + Pharmacist
Study: NCT02555449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3202626
Description: Administered as solution by mouth
Study: NCT03712930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 60 mg orally twice daily (BID)
Study: NCT03479034

Intervention type: OTHER
Intervention: ScalaMed ePrescription application
Description: Mobile phone application (Android and Apple) for storing electronic prescriptions
Study: NCT02986906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% dextrose
Description: Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve
Study: NCT01701882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine/rilpivirine
Study: NCT05201131

Intervention type: PROCEDURE
Intervention: Rezum
Description: Rezum
Study: NCT00158678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IMRT 75 Gy
Description: 50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2
Study: NCT01666418

Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib/Paclitaxel
Study: NCT00158678

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy 70 Gy
Description: 50 Gy in PTV1 and 20 Gy in PTV2
Study: NCT02986906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2cc 0.9% normal saline+3cc Triamcinolone (30mg)
Description: Ultrasound-guided 2cc 0.9% normal saline+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve
Study: NCT00158678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concomitant cisplatin
Description: 100 mg/m2 D1, D22, D43

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concomitant cisplatin
Description: 100 mg/m2 D1, D22, D43
Study: NCT02986906

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: The ultrasound was used for injection guidance
Study: NCT00578799

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kyo-Dophilus
Description: 5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules (potato starch
Study: NCT03752606

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TACHOSIL GROUP
Study: NCT02915952

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zip Surgical Skin Closure Device
Description: The Zip Surgical Skin Closure Device will be used for surgical wound closure in C-Section Surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Sutures
Description: Conventional Sutures will be used for surgical wound closure in C-Section Surgery
Study: NCT00945074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Acupuncture/Moxibustion (fixed protocol)
Description: Acupuncture/Moxibustion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Acupuncture/Moxibustion
Description: Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham/Placebo Acupuncture/Moxibustion
Description: Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
Study: NCT02569619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Diet Intervention
Study: NCT02299765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: patients in arm A will be given gefitinib as target therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: patients in arm A will be given gefitinib as target therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: patients in arm A will be given gemcitabine chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: patients in arm A will be given carboplatin chemotherapy
Study: NCT03230344

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: open flap debridement simultaneously with root canal treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open flap debridement
Description: open flap debridement and delayed root canal treatment
Study: NCT03518814

Intervention type: OTHER
Intervention: Questionnaires
Description: FACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire, MOS SF (medical outcome study short form) -36 questionnaire
Study: NCT04496440

Intervention type: OTHER
Intervention: Contracture Correction Therapy
Description: Non-drug and non-surgical treatment of contracted knee capsules
Study: NCT00358995

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Therapy (SMT)
Description: Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
Study: NCT02986906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The ultrasound was used for injection guidance
Study: NCT00462826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Study: NCT02976532

Intervention type: OTHER
Group type: OTHER
Intervention: Electromagnetic tracking unit in femoral derotation surgery
Description: Use of the electromagnetic tracking system during the surgical procedure in addition to the normal measurement with goniometer, the different devices listed are combined to form the EMT system unit
Study: NCT05900193

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TAS1R2/3 agonist or antagoinst admixture to oral glucose tolerance test
Description: Participants drank a glucose beverage for an oral glucose tolerance test along or with admixture with the TAS1R2/3 agonist sucralose or the TAS1R2/3 antagonist lactisole.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TAS1R2/3 agonist or antagoinst admixture to oral glucose tolerance test
Description: Participants drank a glucose beverage for an oral glucose tolerance test along or with admixture with the TAS1R2/3 agonist sucralose or the TAS1R2/3 antagonist lactisole.
Study: NCT04264767

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Peripheral blood collection via routine venipuncture

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Peripheral blood collection via routine venipuncture
Study: NCT01665521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEART Pathway
Description: During ED evaluation, patients are randomized to HEART Pathway or usual care arms.